The observed incidence of adverse reactions in patients receiving omalizumab therapy in a tertiary allergy and asthma clinic in Canada

被引：0
|
作者：
Harrison, R. [1 ]
Santucci, S. [1 ]
MacRae, M. [1 ]
Yang, W. H. [1 ,2 ]
机构：
[1] Ottawa Allergy Res Corp, Ottawa, ON, Canada
[2] Univ Ottawa, Sch Med, Ottawa, ON K1N 6N5, Canada
来源：
ALLERGY | 2015年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
845
引用
收藏
页码：350 / 351
页数：2
相关论文
共 50 条
  • [1] The Observed Incidence of Anaphylaxis in Patients Receiving Omalizumab in a Tertiary Allergy and Asthma Clinic in Canada
    MacRae, Megan
    Santucci, Stephanie
    Rizk, Caroline
    Karsh, Jacob
    Yang, William H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB4 - AB4
  • [2] An Update On: The Observed Incidence of Anaphylaxis in Patients Receiving Omalizumab in a Tertiary Allergy and Asthma Clinic in Canada
    Valois, Jodi
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB15 - AB15
  • [3] The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
    MacRae M.
    Santucci S.
    Karsh J.
    Yang W.H.
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
  • [4] Omalizumab Enrollment in a Tertiary Care Allergy and Asthma Clinic in Canada
    Hoang Pham
    Cameron, Jodi
    Forgie, Jennifer
    Ring, Alicia
    Diana Pham
    Santucci, Stephanie
    Rizk, Caroline
    O'Quinn, John W.
    Yang, William H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB2 - AB2
  • [5] Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
    Jodi Cameron
    Jennifer Forgie
    Alicia Ring
    Stephanie Santucci
    Caroline Rizk
    Hoang Pham
    John O’Quinn
    William H Yang
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
  • [6] Incidence of SARS-CoV-2 Infection in Asthma Patients on Omalizumab Therapy
    Ozdemir, Öner
    Dikici, Ümmügülsüm
    ERCIYES MEDICAL JOURNAL, 2022, 44 (05) : 533 - 534
  • [7] A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland
    Subramaniam, A.
    Al-Alawi, M.
    Hamad, S.
    O'Callaghan, J.
    Lane, S. J.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2013, 106 (07) : 631 - 634
  • [8] Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
    Lee, Jason K.
    Amin, Suvina
    Erdmann, Michelle
    Kukaswadia, Atif
    Ivanovic, Jelena
    Fischer, Aren
    Gendron, Alain
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 725 - 735
  • [9] The Adherence to Inhaled Corticosteroid Therapy of Patients Referred to a UK Tertiary Asthma Clinic
    D'Ancona, G.
    Laver, J.
    Stewart-Kercher, N.
    Rahman, S.
    Fernandes, M.
    Green, L.
    Thomson, L.
    Roxas, C.
    Nanzer, A.
    Dhariwal, J.
    Jackson, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [10] Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy
    Hamilton, RG
    Marcotte, GV
    Saini, SS
    JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 303 (1-2) : 81 - 91
12345